The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Florence Cymbalista: iwCLL 2019, key points
Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, discusses what the key points of discussion she expects to hear from the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. Dr Cymbalista touches on combination therapies, novel agents and measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) treatment.
